Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Trinity Biotech (TRIB) EBIT Margin (2016 - 2024)

Historic EBIT Margin for Trinity Biotech (TRIB) over the last 16 years, with Q4 2024 value amounting to 72.61%.

  • Trinity Biotech's EBIT Margin fell 444600.0% to 72.61% in Q4 2024 from the same period last year, while for Dec 2024 it was 34.38%, marking a year-over-year increase of 132100.0%. This contributed to the annual value of 34.38% for FY2024, which is 132000.0% up from last year.
  • Latest data reveals that Trinity Biotech reported EBIT Margin of 72.61% as of Q4 2024, which was down 444600.0% from 16.88% recorded in Q3 2024.
  • In the past 5 years, Trinity Biotech's EBIT Margin registered a high of 28.38% during Q3 2020, and its lowest value of 106.86% during Q2 2023.
  • For the 5-year period, Trinity Biotech's EBIT Margin averaged around 17.79%, with its median value being 14.44% (2022).
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by -948600bps in 2023, then surged by 812900bps in 2024.
  • Quarter analysis of 5 years shows Trinity Biotech's EBIT Margin stood at 27.67% in 2020, then tumbled by -90bps to 2.88% in 2021, then tumbled by -1899bps to 51.87% in 2022, then soared by 46bps to 28.14% in 2023, then crashed by -158bps to 72.61% in 2024.
  • Its EBIT Margin was 72.61% in Q4 2024, compared to 16.88% in Q3 2024 and 25.58% in Q2 2024.